首页 | 本学科首页   官方微博 | 高级检索  
     


In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer
Authors:Karen L. R. Paiva,Marina A. Radicchi,Sô  nia N. Bá  o
Affiliation:1.Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, DF, Brazil; (K.L.R.P.); (M.A.R.);2.Postgraduate Program of Molecular Pathology, School of Medicine, University of Brasília, Brasília 70910-900, DF, Brazil;3.Postgraduate Program of Molecular Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, DF, Brazil
Abstract:Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line.
Keywords:solid lipid nanoparticle   triple-negative breast cancer   docetaxel
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号